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ABSTRACT 
International Journal of Exercise Science 14(2): 1375-1387, 2021. Caffeine (CAF) has been extensively 
studied for its ergogenic and analgesic effects during exercise. However, the majority of these studies have been 
conducted in male populations. This study investigated the effects of acute CAF chewing gum on self-selected 
exercise intensity during a rating of perceived exertion (RPE) production trial in active females (n = 16, 21.0 ± 2.8 
y). Data were also analyzed based on habitual CAF consumption level. Participants completed a V̇O2peak trial, 
followed by a familiarization and two randomized, triple-blinded experimental RPE production trials on an arm 
ergometer [clamped resistance, blinded to self-selected cadence (CAD)] with either CAF gum (300 mg; 4.8 ± 0.7 
mg/kg-1 body mass) or placebo (PLA), at a prescribed RPE of 4 and 7 (10 min each). Self-selected CAD did not 
statistically differ (p > 0.05) between CAF or PLA for an RPE4 (37.7 ± 1.6 vs. 37.6 ± 1.6 rev·min-1) or RPE7 (42.9 ± 1.6 
vs. 41.2 ± 1.7 rev·min-1), respectively. There were no statistical differences between treatment groups for any other 
variables, except restlessness rating which was significantly higher (3.5 vs. 2.2; p = 0.03, d = 0.64) for the CAF group 
compared to PLA. Secondary analysis revealed no statistical differences for any variables between habitual 
consumers of low (23 ± 20 mg/day) or mod/high (195 ± 93 mg/day) CAF. Our data support previous studies 
examining CAF in women across different testing modalities and suggest that regardless of habitual CAF 
consumption, females might require higher doses of CAF to replicate subjective and physiological responses 
commonly observed using similar RPE production protocols in male participants. These findings support the need 
for additional investigations into female physiological and perceptual responses following CAF ingestion. 
 




Caffeine (CAF) is well-established as an ergogenic aid in sports performance and has been 
reported to alter mechanisms such as increasing intracellular calcium release from the 
sarcoplasmic reticulum, enhancing lipolytic enzymes and free fatty acid mobilization, and 
blocking adenosine receptors [A1 and/or A2A; (12)]. Among these mechanisms, the most viable 
explanation for an ergogenic potential is CAF effect on the central nervous system as an 
analgesic, acting as an adenosine receptor antagonist. Binding of CAF to the A1 and A2A 
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receptors increases the release of neurotransmitters such as norepinephrine and dopamine and 
synergistically blunts an athlete’s perception of pain and rating of perceived exertion [RPE; (36)]. 
In an athletic context, these mechanisms have far reaching implications as subjective ratings 
such as RPE are well documented as a valid and practical field measure for athletes and coaches 
alike (23). 
 
The “RPE production” model is a generally accepted approach for regulating intensity (32). 
During exercise, individuals are prescribed an RPE and subsequently required to adjust their 
physical perception and cadence (CAD) to match their given RPE. Considering that CAF 
ingestion prior to low-to-moderate intensity exercise (~55-80% V ̇O2peak) attenuates muscle pain 
and RPE during fixed-intensity exercise (4, 11, 16), it is reasonable to speculate that CAF would 
alter self-selected CAD using the RPE production model, although current data are mixed. Data 
from our laboratory (22) found that CAF ingestion (6 mg/kg-1) significantly increased self-
selected cycling workloads at RPEs of 4 (~17%) and 7 (~16%). However, Cole et al. (1996) did 
not demonstrate any statistical changes in mean work output incorporating a similar CAF dose, 
testing modality, and RPE production model [RPEs: 9, 12, and 15; (10)]. Discrepancies are 
common among CAF studies as both authors noted a high inter-individual variability among 
the participants responses to CAF. These studies also incorporated cycling as the primary 
method for assessing changes in RPE regulated workload. Interestingly, a meta-analysis 
demonstrated the ergogenic effects of CAF are more likely to be observed in testing modalities 
incorporating musculature of the lower body compared to the upper body (39). When 
examining the effects of CAF on motor unit recruitment and maximal voluntary contraction in 
knee extensors and elbow flexors, statistical differences are only found in the knee extensors (5, 
39). The lack of an ergogenic effect is likely a result of the near-maximal (> 90%) motor unit 
recruitment in the arms compared to the legs (~80-90%) and therefore, the arms have a smaller 
range for performance improvements to manifest. While only speculation and provided the 
above findings, it would seem appropriate to incorporate the upper body when examining CAF 
in an RPE production model as a means for reducing confounding variables (i.e. improvements 
to motor unit recruitment, strength, neural excitability, etc.) which might affect CAD selection 
and performance. To our knowledge, no study has yet tested this hypothesis. Additional 
discrepancies have also been attributed to individual differences in CAF metabolism and genes 
[i.e. enzyme CYP1A2 and cytochrome P-450; (40)], CAF testing doses [~3-13 mg/kg-1; (34)], 
habitual consumption (17), and subjective responses between genders (38). Indeed, while the list 
of inconsistencies among CAF research is large, most notable is the continued lack of CAF 
research among females. 
 
Recently, Salinero and team (2019) reported that among CAF research and physical 
performance, only ~13% of the total participant pool were females (33). The limited research in 
females creates a gap between sports nutrition and CAF recommendations. Research has 
demonstrated CAF elicits varying responses in females than males (e.g. greater changes to blood 
pressure and negative feelings associated with CAF use), likely due to hormonal shifts through 
the month although specific mechanisms remain unclear (38). Current data also suggests that 
females might require higher doses of CAF when subjective ratings such as RPE are collected 
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and that a lack of CAF responsiveness is observed in females even when categorized by habitual 
CAF consumption (37).   
 
Therefore, the aim of the present study was to investigate the effect of CAF chewing gum on 
CAD selection using recreationally active females during an arm ergometer protocol and the 
RPE production model. A secondary aim was to investigate whether habitual CAF consumption 
altered any potential ergogenic effect in females. The present team hypothesized that CAF 





A total of 16 recreationally active (i.e., ≥ 3 aerobic or resistance training sessions per week, 
greater than 45 min per session) females were recruited to participate in this study (age: 21 ± 2.8 
years; height: 1.66 ± 0.06 m; body mass: 63.9 ± 11.2 kg; body fat: 25.5 ± 6.0%; and V ̇O2peak: 21.8 ± 
2.9 ml·kg-1·min-1). A power analysis (beta = 0.80, alpha = 0.05, standard deviation = 7 rev·min-1, 
and effect size = 5 rev·min-1) showed 15 participants were needed. Preliminary data were 
collected on the initial visit. Participants completed a caffeine consumption questionnaire (8), 
physical activity readiness questionnaire, and a general health and medical questionnaire. 
Additionally, participants were not excluded for taking oral contraceptives and all participants 
verbally agreed they were naturally menstruating and had experienced a regular menstrual 
cycle across the last 3 months, although ovulation was not confirmed by the investigative team. 
Participants then provided the principle investigator with a 24-hour dietary recall.  
 
This study conformed to the standards set by the Declaration of Helsinki, the standards of the 
International Journal of Exercise Science (28), and was approved by the institutional review 
board of the University of North Alabama (IRB #: 076). After inclusion and exclusion criteria 
were met, each participant was informed of the purpose of the study and the following 
procedures required and expected of each participant for the duration of the study. All 
participants then verbally and in writing provided consent to participate in this study. 
 
Protocol 
A double-blind (i.e. research participant and investigator administering treatment), 
counterbalanced, randomized crossover-within design was employed to examine the effects of 
a commercially available CAF chewing gum on CAD selection for all participants with follow-
up between participant analysis for habitual versus sparse CAF consumers. The time of day for 
the experimental trials was standardized for each participant however, the menstrual cycle 
phase was not standardized due to a lack of data demonstrating statistical differences in markers 
of female performance across the menstrual cycle (26). An overview of the study is shown in 
Figure 1.  
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Figure 1. Schematic overview of the experimental protocol. CAF = Caffeine; PLA = Placebo; CAD = Cadence; RPE 
= Rating of Perceived Exertion 
 
In brief, participants were allowed to participate in this study if they met inclusion criteria which 
included: (a) must meet the American College of Sports Medicine low-risk guidelines (27), (b) 
refraining from caffeine and alcohol consumption at least 24-hours before the experimental 
trials, (c) avoiding all strenuous upper-body exercise at least 48-hours before each experimental 
trial, and (d) be considered recreationally active as previously outlined. 
 
Participants were asked to arrive to the laboratory between the hours of 0500 and 0900 in a non-
fasted and well hydrated state (verified verbally each session). Following completion of 
questionnaires and obtaining informed consent, height was assessed to the nearest cm with a 
stadiometer (Deteco, Webb City, MO) and weight to the nearest 0.1 kg with a digital scale (Tanita 
Corporation, Japan). Body fat percentage was estimated using Lange skin fold calipers 
(Cambridge, Maryland) and a 3-site method [tricep, iliac, and thigh; (30)].  
 
Following collection of anthropometrics, participants were then fitted with a heart rate (HR) 
(H10; Polar Electro Inc., Lake Success, NY, USA) monitor across their sternum and 
cardiorespiratory measures were collected using a Parvomedics TrueOne 2400 (Parvomedics, 
Sandy, UT). Correct form and posture were achieved by adjustment of seat height on the 
Monark arm crank ergometer (Monark Exercise 881E Rehab Trainer, Langley, WA). Handlebar 
position was adjusted to personal preference. Participants then completed a maximal exercise 
test on the arm ergometer to determine peak oxygen consumption (V ̇O2peak). Cycling began with 
participants required to maintain 50 ± 5 rev·min-1during the entire test. The first stage lasted for 
2 min at a set workload of 15 W. After the initial stage, three consecutive stages followed which 
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lasted 3 min each and increased by 25 W, respectively. Following stage four, resistance then 
increased by 25 W every min until participants reached volitional exhaustion or could no longer 
maintain 50 rev·min-1 when provided verbal encouragement. Participants were then allowed a 
passive 10 min cool-down period before completing a modified familiarization trial which 
mimicked the experimental trials, but was shorter in duration by 5 minutes. 
 
Following the V ̇O2peak test, participants were instructed to arrive to the lab after a minimum of 
24-hours with directions to be well-rested, hydrated, and following at least a four hour fast. 
Additionally, the principle investigator contacted each participant 24-hours prior to their 
experimental trial and provide each participant their respective food logs to replicate before 
experimental testing the next day. Participants verbally verified these instructions prior to each 
visit. Participants donned appropriate instruments for the collection of metabolic data and HR, 
followed by seat and handlebar adjustment as described earlier. With the RPE scale in full view 
and information on the arm ergometer concealed, participants began the warm-up for 2 min at 
a self-selected pace. Following the warm-up, participants were then allowed a titration period 
(~3 min) and asked to gradually adjust cadence to produce an overall RPE of 4 on the OMNI 
Scale (6). At the completion of the titration period and following verbal confirmation from each 
participant they had achieved the prescribed RPE, participants then began a 10 min production 
trial (RPE4). The current RPE production model was adopted and modified for the Monark arm 
ergometer (18). Resistance for each RPE production trial was individualized and chosen based 
on previously published research (18). Using each participant’s peak V ̇O2, 50 rev·min-1, and 
metabolic equations (27), a resistance was selected which approximated a 50% V ̇O2 for RPE4 and 
70% V ̇O2 for RPE7. These intensities were clamped for each production trial and expected to fall 
below each participant’s threshold where premature fatigue would occur and disrupt the trial. 
Metabolic data [i.e. V ̇O2 and respiratory exchange ratio (RER)], HR, CAD, and RPE were 
recorded every 2 min (5 stages). Following completion of the 10 min production trial, 
participants dismounted the arm ergometer and removed metabolic collection equipment and 
allowed a 10 min bout of passive recovery. After the recovery period, participants then 
completed an identical 2 min warm-up and 3 min titration period before starting a 10 min, RPE 
production trial of 7 (RPE7) where identical markers were collected every 2 min. Verbal 
encouragement was not provided from the investigators during the RPE production trials. Upon 
completion of the RPE production trial, participants completed a CAF questionnaire using a ten-
point Likert scale (19). For each question (fatigue, nervousness, restlessness, elevated mood, 
tremors, stomach distress), a zero represented not experiencing any symptom and a ten 
represented intense experience of the symptom. The final question provided each participant 
with an opportunity to choose which supplement [CAF vs. placebo (PLA)] they received during 
the trial. 
 
Participants were given either 3 pieces of CAF gum (1 stick of gum = 100 mg CAF; 300 mg CAF 
total) or non-CAF PLA gum (Military Energy Gum; MarketRight Inc. Plano, IL, USA) 
approximately 15 min before performing the RPE production trials. Earlier studies examining 
the pharmacokinetics of CAF gum have shown 85% CAF release within 5 min of chewing and a 
90% bioavailability profile (20, 34), making CAF gum a practical supplement prior to 
competition compared to the 60 min duration generally needed with anhydrous capsules or 
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powder. Both gum varieties were identical in taste, smell, and color. A researcher not involved 
with the RPE production trial administered the gum to each participant. All participants had 
previous experience with energy drinks, coffee, pre-workout supplements, and teas, but no 
participant had experience with CAF gum. However, following completion of the study, 9 of 
the 16 participants (56%) correctly guessed the CAF gum due to a bitter aftertaste left in the 
participants mouth once the gum had been expelled. Based on each participant’s body mass, the 
dose of CAF used in the present study averaged 4.8 ± 0.7 mg/kg-1 and ranged from 3.1 to 5.8 
mg/kg-1. An absolute CAF dosage (300 mg) vs. a relative (mg/kg-1) was chosen to best replicate 
athlete practices before a sporting event.  
 
Statistical Analysis 
Data are reported as mean ± SD. The α level was set at p ≤ 0.05 to be considered statistically 
significant. Data were tested for normality using the Shapiro-Wilk’s test prior to proceeding 
with the parametric tests as described. Sphericity was evaluated using Mauchly’s test and 
Greenhouse-Geisser adjustments were used where appropriate. Data were first analyzed as a 
whole group (n = 16), regardless of CAF habitual consumption. To compare CAD (rev·min-1), 
HR (bpm), V ̇O2 (ml·kg-1·min-1), and RER between CAF and PLA, a 2 × 5 (treatment [PLA vs. 
CAF] × time point [5 stages]) repeated-measures analysis of variance (RMANOVA) were 
conducted using SPSS (Version 26; IBM, Chicago, IL). Where appropriate, follow-up paired t 
tests were used to compare specific time points between trials. Paired t tests were also used to 
compare Likert scale responses (treatment [PLA vs. CAF]). To examine whether the treatment 
had a true effect on CAD selection, dependent t tests (time [Trial 1 vs. Trial 2]) were carried out 
to identify the trial order effects, if any. Cohen’s d (d: 0.2 = small, 0.5 = moderate, and 0.8 = large 
effect) were calculated to provide effect sizes for an interpretation of meaningful differences (9). 
To assess individual responses to CAF (vs. PLA), we calculated a least significant difference 
(LSD) for each prescribed intensity (RPE4 and RPE7). Mean values for individual participants 
across stages were calculated for CAF and PLA and a pooled standard deviation was 
determined. The LSD was calculated using the pooled standard deviation, alpha 0.05, beta 0.8, 
along with the number of participants (n = 16). For RPE4 the LSD was 4.4 and for RPE7 the LSD 
was 4.9. These values served as criterion values for each intensity. Differences less than these 
criterion values were ‘non-responders’. Differences greater than or equal to these values were 
labeled as ‘positive responders’ (improved as result of CAF) or ‘negative responders’ (lower 
CAD as result of CAF). A secondary analysis by low (n = 8; <50 mg/day; 23 ± 20 mg/day) and 
mod/high (n = 8; ≥100 mg/day; 195 ± 93 mg/day) habitual CAF consumption was then 
performed. Percentage change in performance between PLA and CAF trials were calculated as 
[(Difference in CAF and PLA)/PLA*100]. These data were then incorporated into a mixed-
model ANOVA to examine interaction effects, within participant effects for time points, and 
between participant effects for habitual (low vs. mod/high) CAF consumption. Analyses were 
completed for both RPE4 and RPE7. If significant interaction or main effects for treatment were 
found, independent t tests were used to determine which stages exhibited significant differences 
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An order effect was not found for our main dependent variable CAD at either RPE of 4 or 7 
(Table 1). As a whole group and for an RPE4, main effects for time points were found for HR 
and V ̇O2 (p < 0.01), but no main effect or interaction effects were found for either parameter (p > 
0.05). Additionally, there were no significant treatment × time point interactions, main effects, 
or time point differences for either RER or CAD (p > 0.05).  
 
At an RPE7, main effects for time points were found for HR, V ̇O2, and RER (p < 0.05), but not for 
CAD. Regarding RER, stage 1 was higher than stage 5 (1.04 ± 0.01 vs. 0.99 ± 0.01; p = 0.004), 
however no additional differences were found between time points. There were no significant 
treatment × time point interactions or main effects for HR, RER, CAD, or V ̇O2 (p > 0.05).  
 
The LSD criteria for each intensity allowed for identification of individual responses to CAF. 
RPE4 LSD comparisons resulted in 25% (n = 4) of the 16 participants being positive responders 
and 12.5% (n = 2) being negative responders to CAF. For RPE7, there were 12.5% (n = 2) positive 
responders (one approaching the criteria with a delta of 4.6) and zero negative responders 
(though one approached the criterion with -4.2).  
 
Regarding subjective measurements, statistical differences were found for Likert scale data 
(Table 2). Specifically, participants as a whole group experienced a significantly increased sense 
of restlessness during the CAF trial vs. PLA (t = 2.36, p = 0.03, d = 0.64). All other variables 
(fatigue, mood, nervousness, tremors, distress) demonstrated no statistical differences, although 
mood approached significance (p = 0.06) in the CAF vs. PLA group (6.3 ± 1.5 vs. 5.3 ± 1.5), 
respectively.  
 
Following secondary analysis, there were no significant main effects in percentage performance 
changes for stage or low vs. mod/high CAF consumers for CAD, HR, RER, or V ̇O2 during RPE4 
or RPE7. There was a significant interaction for RPE7 V ̇O2 (p = 0.009; Table 3). Follow up analyses 
revealed a higher percentage change for mod/high vs. low CAF consumers during stage 3 (p = 
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Table 1. Comparison of performance and physiological variables in college females during PLA vs. CAF trials 
(mean ± SD). 
 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
    RPE - 4 
CAD 
  CAF 
  PLA 
 
38.3 ± 7.4 
37.3 ± 6.0 
 
37.7 ± 7.4 
38.3 ± 6.2 
 
37.9 ± 6.1 
37.9 ± 6.5 
 
37.4 ± 6.0 
37.2 ± 6.7 
 
37.3 ± 5.6 
37.1 ± 6.4 
Heart Rate 
  CAF 
  PLA 
 
112.0 ± 20.0 
117.0 ± 14.0 
 
118.0 ± 22.0 
121.0 ± 17.0 
 
120.0 ± 22.0 
124.0 ± 18.0 
 
123.0 ± 24.0 
125.0 ± 20.0 
 
124.0 ± 23.0 
125.0 ± 20.0 
VO2 
  CAF 
  PLA 
 
10.6 ± 1.9 
10.4 ± 2.1 
 
10.6 ± 2.3 
10.9 ± 2.1 
 
10.9 ± 2.9 
11.1 ± 2.2 
 
11.4 ± 2.2 
10.8 ± 2.4 
 
11.4 ± 2.2 
11.2 ± 2.4 
RER 
  CAF 
  PLA 
 
0.98 ± 0.08 
0.98 ± 0.05 
 
0.98 ± 0.05 
0.97 ± 0.05 
 
0.97 ± 0.05 
0.97 ± 0.04 
 
0.97 ± 0.05 
0.97 ± 0.06 
 
0.96 ± 0.04 
0.97 ± 0.04 
    RPE - 7 
CAD 
  CAF 
  PLA 
 
43.6 ± 7.2 
42.3 ± 6.3 
 
43.0 ± 7.5 
40.6 ± 6.9 
 
42.4 ± 5.9 
41.6 ± 7.8 
 
42.4 ± 7.0 
41.5 ± 7.2 
 
43.1 ± 8.3 
40.3 ± 7.1 
Heart Rate 
  CAF 
  PLA 
 
138.0 ± 22.0 
137.0 ± 21.0 
 
142.0 ± 22.0 
140.0 ± 23.0 
 
148.0 ± 19.0 
142.0 ± 23.0 
 
151.0 ± 19.0 
144.0 ± 24.0 
 
153.0 ± 20.0 
147.0 ± 24.0 
VO2 
  CAF 
  PLA 
 
14.2 ± 2.5 
13.9 ± 2.8 
 
15.0 ± 3.0 
14.0 ± 3.3 
 
15.7 ± 3.7 
14.8 ± 3.3 
 
15.6 ± 3.3 
14.5 ± 2.6 
 
15.7 ± 3.7 
14.9 ± 2.8 
RER 
  CAF 
  PLA 
 
1.03 ± 0.06 
1.04 ± 0.06 
 
1.03 ± 0.07 
1.02 ± 0.05 
 
1.02 ± 0.06 
1.00 ± 0.06 
 
1.01 ± 0.06 
1.00 ± 0.07 
 
1.01 ±.0.06 
0.99 ± 0.05 
  
 
Table 2. Comparison of subjective responses in college females during PLA vs. CAF trials (mean ± SD). 
Variables CAF PLA p d 
Fatigue 6.0 ± 1.9 6.3 ± 2.1 .60 0.15 
Mood 6.3 ± 1.5 5.3 ± 1.5 .06 0.67 
Nervousness 1.8 ± 1.8 1.5 ± 1.4 .60 0.19 
Restlessness 3.5 ± 1.9 2.2 ± 2.3 .03* 0.62 
Tremors 2.4 ± 2.6 1.5 ± 2.3 .19 0.37 
Distress 1.2 ± 1.9 .81 ± 1.9 .56 0.21 
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Table 3. Comparison of delta change as percentage of performance and physiological variables of low CAF 
consumers (n = 8) and mod/high CAF consumers (n = 8) during PLA vs. CAF trials (mean ± SD). 
 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5  





4.8 ± 14.5 
2.8 ± 26.4 
 
6.5 ± 14.0 
-7.1 ± 18.6 
 
5.3 ± 14.2 
-1.7 ± 14.4 
 
4.4 ± 14.8 
-0.2 ± 7.3 
 
4.6 ± 17.1 






-3.4 ± 13.4 
-4.8 ± 16.5 
 
-1.3 ± 10.7 
-4.8 ± 15.6 
 
-0.3 ± 10.0 
-4.6 ± 14.8 
 
2.7 ± 8.8 
-4.5 ± 13.9 
 
2.1 ± 7.6 






7.7 ± 13.4 
-0.2 ± 28.2 
 
2.5 ± 11.4 
-4.0 ± 28.8 
 
15.6 ± 19.8 
-8.5 ± 20.9 
 
12.5 ± 16.7 
4.5 ± 32.6 
 
6.2 ± 14.4 






0.3 ± 8.4 
0.9 ± 10.3 
 
1.5 ± 5.2 
1.1 ± 8.6 
 
1.0 ± 5 
0.3 ± 8.2 
 
1.6 ± 5.6 
-0.8 ± 7.1 
 
1.8 ± 4.9 
-2.1 ± 2.8 
 





7.1 ± 11.7 
-0.5 ± 4.0 
 
13.2 ± 15.2 
0.7 ± 11.7 
 
8.1 ± 16.9 
-0.6 ± 8.5 
 
4.6 ± 17.1 
1.6 ± 9.3 
 
6.1 ± 12.7 






2.5 ± 7.3 
-0.1 ± 16.1 
 
4.3 ± 8.0 
-0.4 ± 15.8 
 
8.4 ± 11.8 
2.3 ± 16.1 
 
8.3 ± 10.9 
3.1 ± 13.1 
 
8.2 ± 10.6 






11.2 ± 10.4* 
-2.9 ± 15.9 
 
17.3 ± 11.6* 
0.8 ± 21.7 
 
16.6 ± 14.2‡ 
-1.0 ± 18.2 
 
7.6 ± 14.2 
8.9 ± 17.3 
 
7.0 ± 18.5 






1.0 ± 4.9 
-1.1 ± 6.4 
 
-0.2 ± 5.4 
2.2 ± 6.1 
 
0.6 ± 5.4 
3.9 ± 5.7 
 
2.1 ± 4.7 
0.9 ± 7.2 
 
1.7 ± 5.3 
2.2 ± 6.7 
 
† = Significant interaction effect for group-treatment (p = 0.009). 
‡ = Significant difference (p = 0.05) between low and mod/high CAF consumers. 





The primary aim of the present study was to examine the effects of CAF (300 mg) on CAD 
selection in recreationally active females during an RPE production trial (RPE4 and RPE7). Our 
secondary aim was to investigate whether habitual CAF consumption altered any potential 
ergogenic effect in females. When analyzed as an entire cohort, our data demonstrate that acute 
ingestion of CAF chewing gum resulted in no meaningful differences regarding HR, RER, V ̇O2, 
or CAD selection during either RPE production trial (Table 1). However, the present group did 
experience a moderate level (d = 0.64) of restlessness compared to PLA (Table 2). Although 
mod/high doses of CAF ingestion are well known to induce elevated states of anxiety, 
restlessness, and tremors (29), these findings may have further implications as it relates to female 
performance. Provided the strong relationship between an individual’s precompetition 
subjective state (i.e. optimal arousal threshold) and their subsequent performance in 
competition, it may be that an elevated level of restlessness would hamper competition 
performance although additional research investigating this specific area in females is needed. 
Moreover, secondary analysis found no differences when comparing habitual CAF 
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consumption in females on all dependent variables. Current literature recommends an acute 
ingestion of ~3-9 mg/kg-1 of CAF prior to exercise to improve performance (12). However, 
ingesting a similar CAF dose within the suggested ranges demonstrated no changes to CAD 
regardless of habitual consumption. Our results, albeit only a single study, showed a lack of 
ergogenicity from acute, moderately-dosed CAF ingestion in recreationally-active females.  
 
Results examining the effect of CAF ingestion and performance in female populations is scarce 
(~13%) with equivocal outcomes (2, 34). A recent review outlined these discrepancies which 
include the CAF dose, time of day, modality of testing, habitual consumption, and 
environmental conditions (29). Although as a group, our participants demonstrated no changes 
to CAD with CAF or PLA, this study also appears to be the first to examine female habitual CAF 
consumption on subjective responses and CAD selection. Following secondary analysis, our 
data demonstrated no statistical differences in our primary dependent variable (i.e. CAD 
selection) between low and mod/high habitual CAF consumption. These findings are in 
contrast to Evans et al. (2018) who recently demonstrated an ergogenic effect of CAF chewing 
gum in male athletes with low, but not high habitual CAF consumption (13). This study is 
particularly interesting as these data demonstrated a low-absolute CAF dose (2 gum pieces; 200 
mg) mitigated decrements to repeated sprint performance (18%). Although the present study 
and Evans et al. (2018) implemented different testing modalities and intensities [repeated sprints 
(~95%) vs. RPE production trials (50 and 70%)], both studies incorporated relatively low-
absolute CAF doses (300 vs. 200 mg) compared to typical relative CAF ranges (+6 mg/kg-1) and 
both had similar ranges for habitual low CAF consumers (23 ± 20 vs. 22 ± 12 mg/day), 
respectively (13). However, our study incorporated a female only cohort, whereas Evans et al. 
(2018) incorporated an all-male cohort. The differences in genders are important to identify for 
future CAF investigations, since the hormonal fluctuations in females are known to impact 
subjective feelings following CAF ingestion and often require females to ingest higher CAF 
doses to replicate similar subjective states observed in males (38). These data are important as 
our low habitual (relative CAF dose: 4.7 ± 0.5 mg/kg-1) and mod/high habitual (relative CAF 
dose: 4.9 ± 0.9 mg/kg-1) consumers ingested relative CAF gum doses within the recommended 
sport nutrition guidelines (~3-6 mg/kg-1) to induce an ergogenic effect prior to exercise and yet, 
no effect was found. It is worth speculating that higher doses of CAF might be required in female 
participants to elicit similar physiological and subjective responses when incorporating an RPE 
production trial.  
 
Indeed, a major limitation to the current body of CAF and performance literature is that among 
21 studies included in a systematic review (15), less than 10% included female participants. This 
is likely due to the influence of the menstrual cycle and use of oral contraceptives in CAF 
metabolism, making female participants a more complex cohort for CAF research. The current 
pooled literature does not provide evidence that a woman’s menstrual cycle or use of oral 
contraceptives meaningfully impacts her performance. Regardless, both variables are often cited 
as factors which should be controlled for in CAF studies as each have been shown to affect CAF 
metabolism (29). Whether similar CAF doses elicit identical subjective and physiological 
responses between both sexes remains unclear. Steroid hormone status has been shown to 
influence CAF metabolism, with a delay in CAF clearance during the luteal phase (21). It has 
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been suggested that the rise in estradiol and progesterone during the luteal phase impairs the 
primary metabolic pathway of CAF, Cytochrome P-450 (21). There also appears to be a stronger 
link between oral contraceptive use and a delay in CAF metabolism (31) which presents a 
limitation to the current study. On average, 50-70% of college-age females take an oral 
contraceptive (14). Our team purposefully did not include/exclude potential female participants 
for oral contraceptive use to best represent a randomized sample of active, college-females. Oral 
contraceptives dramatically reduce the clearance rate of CAF and has led investigators to 
recommend longer durations between CAF ingestion and performance trials (29). These data 
are important when incorporating CAF gum which peaks in plasma concentrations between 5-
15 min, compared to ~45 min with capsules (20). Whether an elevation of plasma CAF 
accumulation meaningfully influences its ergogenic properties is currently unknown. However, 
due to our incorporation of a 15 min duration between CAF gum ingestion and exercise, it is 
reasonable to assume that some of our participants were taking oral contraceptives which 
potentially delayed CAF metabolism, masked any changes to CAD, and resulted in a Type II 
error.  
 
In conclusion, our results suggest that CAF gum ingestion (300 mg), 15 min prior to an RPE 
production trial provided no benefit to subjective responses or CAD in active females. 
Additionally, these results did not differ between habitual consumers of low or mod/high CAF. 
The present study does not refute the large body of evidence demonstrating the erogenicity of 
CAF in both male and female athletes. Rather, our data are intended to add to the lack of CAF 
research in active females and to suggest that current CAF recommendations need additional 
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